Ulcerative Colitis Stocks List

Ulcerative Colitis Stocks Recent News

Date Stock Title
Jun 17 IMMX Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Jun 17 FBIO Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
Jun 17 HCM HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
Jun 16 BHC With 63% ownership of the shares, Bausch Health Companies Inc. (NYSE:BHC) is heavily dominated by institutional owners
Jun 16 ABBV 2 Dividend Stocks That Could Pay You for Life
Jun 15 ABBV ALS therapy market seen increasing to nearly $1.3B by 2029
Jun 15 PTGX We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation
Jun 14 ABBV AbbVie urges shareholders to reject mini-tender offer
Jun 14 ABBV AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
Jun 14 BHC Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Jun 14 ABBV Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Jun 14 ABBV AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
Jun 14 ABBV AbbVie joins in latest gastrointestinal drug chase
Jun 14 LXRX Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
Jun 14 LXRX Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
Jun 14 ABBV AbbVie and FutureGen link on inflammatory bowel disease
Jun 14 PTGX Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Jun 13 ABBV Here's How Many Shares Of AbbVie You Would Need To Earn $500 Per Month In Dividends
Jun 13 ABBV AbbVie inks licensing pact for bowel disorder therapy
Jun 13 ABBV AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
Ulcerative Colitis

Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur. Often, symptoms come on slowly and can range from mild to severe. Symptoms typically occur intermittently with periods of no symptoms between flares. Complications may include megacolon, inflammation of the eye, joints, or liver, and colon cancer.The cause of UC is unknown. Theories involve immune system dysfunction, genetics, changes in the normal gut bacteria, and environmental factors. Rates tend to be higher in the developed world with some proposing this to be the result of less exposure to intestinal infections, or to a Western diet and lifestyle. The removal of the appendix at an early age may be protective. Diagnosis is typically by colonoscopy with tissue biopsies. It is a kind of inflammatory bowel disease (IBD) along with Crohn's disease and microscopic colitis.Dietary changes, such as maintaining a high-calorie diet or lactose-free diet, may improve symptoms. Several medications are used to treat symptoms and bring about and maintain remission, including aminosalicylates such as mesalazine or sulfasalazine, steroids, immunosuppressants such as azathioprine, and biologic therapy. Removal of the colon by surgery may be necessary if the disease is severe, does not respond to treatment, or if complications such as colon cancer develop. Removal of the colon and rectum can cure the disease.Together with Crohn's disease, about 11.2 million people were affected as of 2015. Each year it newly occurs in 1 to 20 per 100,000 people, and 5 to 500 per 100,000 individuals are affected. The disease is more common in North America and Europe than other regions. Often it begins in people aged 15 to 30 years, or among those over 60. Males and females appear to be affected in equal proportions. It has also become more common since the 1950s. Together, ulcerative colitis and Crohn's disease affect about a million people in the United States. With appropriate treatment the risk of death appears the same as that of the general population. The first description of ulcerative colitis occurred around the 1850s.

Browse All Tags